Edonerpic, formerly known as T-817, is a neuroprotectant. Edonerpic is a candidate therapeutic agent for Alzheimer's disease that inhibits oxidative stress and nitric oxide-induced neurotoxicity and acts as a neurotrophic factor. Edonerpic protects against MPTP-induced neurotoxicity by blocking lipid peroxidation in the SNc, and imply that this compound may be useful for treating neurodegenerative disorders related to oxidative stress, such as Parkinson's disease.
Physicochemical Properties
| Molecular Formula | C20H25NO6S |
| Molecular Weight | 407.481 |
| Exact Mass | 407.14 |
| CAS # | 519187-97-4 |
| Related CAS # | 519187-23-6;519187-97-4; |
| PubChem CID | 11338749 |
| Appearance | White to off-white solid powder |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 9 |
| Heavy Atom Count | 28 |
| Complexity | 415 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | C1C(CN1CCCOCCC2=CC3=C(C=C2)SC=C3)O.C(=C\C(=O)O)\C(=O)O |
| InChi Key | 1-(3-(2-(benzo[b]thiophen-5-yl)ethoxy)propyl)azetidin-3-ol maleate |
| InChi Code | RLUCYBFCLXANSO-BTJKTKAUSA-N |
| Chemical Name | T-817 maleate T-817 T 817 T817 J2.179.155E T-817MA Edonerpic Edonerpic maleate |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | In the presence of Aβ, therapy with edonerpic maleate (T-817MA) maintains cortical neurons (1-42). Neuronal mortality caused by oxidative stress was avoided by a 24-hour pretreatment and sustained administration of 0.1 and 1 μM Edonerpic maleate. At 0.1 and 1 μM, edonerpic maleate virtually entirely inhibits GSH reduction. Comparing hippocampal slices treated with 1 μM edonerpic maleate to control slices, the former generated longer and more neurites. Significant increases in neurite length are observed at 0.1 and 1 μM for edonerpic maleate [1]. |
| ln Vivo | Post hoc testing showed that the average density of PSA-positive cells in the vehicle group and Aβ infusion + high-dose Edonerpic maleate (T-817MA) group was considerably greater than that in the Aβ infusion control group (P<0.01). The outcomes demonstrated that both the vehicle and Aβ infusion + high-dose Edonerpic maleate groups demonstrated robust neurogenesis and effective learning in a place learning task (PLT). Treatment with Edonerpic maleate and donepezil did not increase the average density of normal granulosa cells; Aβ infusion control group, Aβ infusion + high-dose Edonerpic maleate group, Aβ infusion + low-dose Edonerpic maleate group There was no significant difference in the average granule cell density between the Aβ infusion + donepezil group [2]. |
| References |
[1]. A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol maleate] attenuates amyloid-beta-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons. J Pharmacol Exp Ther. 2005 Jul;314(1):252-9. [2]. T-817MA, a neurotrophic agent, ameliorates the deficits in adult neurogenesis and spatial memory in rats infused i.c.v. with amyloid-beta peptide. Br J Pharmacol. 2009 Jun;157(3):451-63. |
Solubility Data
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~245.41 mM) H2O : ~100 mg/mL (~245.41 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.14 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.14 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 3: 140 mg/mL (343.58 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4541 mL | 12.2705 mL | 24.5411 mL | |
| 5 mM | 0.4908 mL | 2.4541 mL | 4.9082 mL | |
| 10 mM | 0.2454 mL | 1.2271 mL | 2.4541 mL |